NasdaqCM · Biotechnology

Crescent Biopharma Inc (CBIO)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+78.4%

$30.60 average target

$17.15+0.92 (+5.7%)Latest market snapshot · Yahoo Finance

Market cap$637.0M

Cash$171.6M

Quarterly burn$19.5M

Pipeline assets5

Short float16.0%

Latest coverage

News & Press Releases

External sources

Aug 3, 2026

Crescent Biopharma Announces Grants of Inducement AwardsGlobeNewswire

Jul 30, 2026

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire

Jul 30, 2026

Crescent Biopharma: Q2 Earnings SnapshotAssociated Press

Continue with BioPharma ProUnlock 7 more recent stories and press releases.

Unlock Pro

Company profile

About Crescent Biopharma Inc

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.